1. Home
  2. ONMD vs BTAI Comparison

ONMD vs BTAI Comparison

Compare ONMD & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneMedNet Corp

ONMD

OneMedNet Corp

HOLD

Current Price

$0.65

Market Cap

35.9M

Sector

N/A

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.88

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONMD
BTAI
Founded
2006
2017
Country
United States
United States
Employees
23
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.9M
35.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ONMD
BTAI
Price
$0.65
$0.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
298.1K
1.5M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.74
52 Week High
$4.22
$8.08

Technical Indicators

Market Signals
Indicator
ONMD
BTAI
Relative Strength Index (RSI) 44.07 37.81
Support Level $0.59 $0.74
Resistance Level $0.96 $1.37
Average True Range (ATR) 0.07 0.13
MACD 0.00 -0.03
Stochastic Oscillator 21.87 19.77

Price Performance

Historical Comparison
ONMD
BTAI

About ONMD OneMedNet Corp

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: